Browsing by Author Larkin, James

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 10 of 10
Issue DateTitleAuthor(s)Citation
2014Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaLong, Georgina; Chiarion-Sileni, Vanna; De Braud, Filippo; et al, Various; Garbe, Claus; Gogas, Helen; Grob, Jean Jacques; Hauschild, Axel; Jouary, Thomas; Larkin, James; Levchenko, Evgeny; Stroyakovskiy, Daniil; Central Clinical School: The Sydney Cancer CentreCombined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma, The New England Journal of Medicine, vol.371, 20, 2014,pp 1877-1888
2015Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaCarlino, Matteo; Long, Georgina; Chiarion-Sileni, Vanna; Cowey, C. Lance; Dummer, R; et al, Various; Gonzalez, Rene; Grob, Jean-Jacques; Lao, Christopher; Larkin, James; Schadendorf, Dirk; Smylie, Michael; Western Clinical School: Medicine (Westmead); Central Clinical School: The Sydney Cancer CentreCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, The New England Journal of Medicine, vol.373, 1, 2015,pp 23-34
2015Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialLong, Georgina; Chiarion-Sileni, Vanna; De Braud, Filippo; et al, Various; Garbe, Claus; Gogas, Helen; Grob, Jean-Jacques; Hauschild, Axel; Jouary, Thomas; Larkin, James; Levchenko, Evgeny; Stroyakovskiy, Daniil; Central Clinical School: The Sydney Cancer CentreDabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial, The Lancet, vol.386, 9992, 2015,pp 444-451
2016Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapyCarlino, Matteo; Long, Georgina; Atkinson, Victoria; Bowyer, Samantha; et al, .; Khou, M.; Larkin, James; Lorigan, Paul; McArthur, Grant A.; Millward, Michael; Prithviraj, P.; Western Clinical School: Medicine (Westmead); Central Clinical School: The Sydney Cancer CentreEfficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy, British Journal of Cancer, vol.114, 10, 2016,pp 1084-1089
2017Health-related quality of life results from the phase III CheckMate 067 studyLong, Georgina; Chiarion-Sileni, Vanna; Cowey, C; et al, Various; Gonzalez, R; Grob, Jean-Jacques; Hodi, F. Stephen; Larkin, James; Rutkowski, Piotr; Schadendorf, Dirk; Wolchok, Jedd D.; Northern Clinical School: MedicineHealth-related quality of life results from the phase III CheckMate 067 study, European Journal of Cancer, vol.82, N/A, 2017,pp 80-91
2017Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression Analysis of 2 Phase 3 Clinical TrialsLong, Georgina; Atkinson, V; Dummer, R; et al, Various; Grob, Jean Jacques; Larkin, James; Márquez-Rodas, Ivan; McNeil, Catriona M.; Robert, Caroline; Schadendorf, Dirk; Schmidt, Henrik; Weber, Jeffrey; Northern Clinical School: MedicineNivolumab for Patients With Advanced Melanoma Treated Beyond Progression Analysis of 2 Phase 3 Clinical Trials, JAMA Oncology, vol.3, 11, 2017,pp 1511-1519
2017Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)Carlino, Matteo; Long, Georgina; Arance, A; Daud, Adil; et al, Various; Grob, Jean Jacques; Larkin, James; Lotem, Michal; McNeil, Catriona M.; Mortier, Laurent; Ribas, Antoni; Schachter, Jacob; Western Clinical School: Medicine (Westmead); Northern Clinical School: MedicinePembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006), The Lancet, vol.390, 10105, 2017,pp 1853-1862
2015Pembrolizumab versus ipilimumab in advanced melanomaCarlino, Matteo; Long, Georgina; Arance, Ana; Daud, Adil; et al, Various; Grob, Jean Jacques; Larkin, James; Lorigan, Paul; Lotem, Michal; McNeil, Catriona; Mortier, Laurent; Neyns, Bart; Robert, Caroline; Schachter, Jacob; Western Clinical School: Medicine (Westmead); Central Clinical School: The Sydney Cancer CentrePembrolizumab versus ipilimumab in advanced melanoma, The New England Journal of Medicine, vol.372, 26, 2015,pp 2521-2532
2016Survival of patients with advanced metastatic melanoma: The impact of novel therapiesLong, Georgina; Ascierto, Paolo; et al, Various; Flaherty, Keith; Grob, Jean-Jacques; Hauschild, Axel; Larkin, James; Lorigan, Paul; McArthur, Grant A.; Rohmel, Joachim; Ugurel, Selma; Northern Clinical School: MedicineSurvival of patients with advanced metastatic melanoma: The impact of novel therapies, European Journal of Cancer, vol.53, N/A, 2016,pp 125-134
2017Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017Long, Georgina; Ascierto, Paolo; et al, Various; Flaherty, Keith; Grob, Jean-Jacques; Hauschild, Axel; Larkin, James; Lorigan, Paul; McArthur, Grant A.; Rohmel, Joachim; Ugurel, Selma; Northern Clinical School: MedicineSurvival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017, European Journal of Cancer, vol.83, N/A, 2017,pp 247-257